Non-Hormonal Induction of Reversible Amenorrhea via Targeted Intrauterine Delivery of Matrix Metalloproteinase Inhibitors, Tie-2 Agonists, and Local Mitotic Quiescence: A Novel Therapeutic Hypothesis

Current therapeutic strategies for inducing reversible amenorrhea or managing severe uterine bleeding disorders depend almost exclusively on systemic endocrine suppression, inevitably causing metabolic, cardiovascular, bone density, and psychological sequelae. This paper introduces a paradigm-shifting therapeutic hypothesis: functional menstruation is an enzymatically driven microvascular remodeling cascade rather than an inescapable endocrine necessity, and it can be reversibly arrested without disrupting the hypothalamic-pituitary-ovarian (HPO) axis or ovulatory cycling. We propose a localized, non-hormonal tripartite pharmacotherapy sustained via an intrauterine, mucoadhesive, thermosensitive hydrogel: (1) Localized broad-spectrum matrix metalloproteinase (MMP) inhibition (targeting MMP-1, MMP-2, MMP-3, and MMP-9) to arrest extracellular matrix catabolism and preserve vascular basement membranes; (2) Tie-2 receptor agonism via an angiopoietin-1 mimetic peptide (e.g., Vasculotide) to maintain spiral arteriole junctional stability and prevent endothelial leakage; and (3) Transient local mitotic quiescence achieved via targeted, low-dose CDK4/6 inhibition (e.g., palbociclib) to maintain endometrial functionalis thickness below 4 mm and prevent unopposed estrogen-driven hyperplasia without inducing apoptosis or permanent senescence. Crucially, this mechanism restricts pharmacodynamic activity entirely to the luminal compartment, leaving the underlying basalis layer and SUSD2+ endometrial mesenchymal stem/progenitor cells intact, thereby safeguarding against Asherman syndrome or fibrotic scarring. Pharmacokinetic clearance of the hydrogel platform permits prompt restoration of standard physiological shedding and cyclical regeneration within 1–2 ovulatory cycles. This framework provides the theoretical and molecular foundation for in vitro and in vivo validation, opening unprecedented frontiers in non-hormonal gynecological therapeutics.